President Trump surprised many people a few weeks ago when he signed an executive order accelerating research into psychedelics. Compounds like psilocybin, LSD, MDMA, ketamine, and others have developed large and enthusiastic followings in the past decade, and some seem quite promising in the treatment of depression, PTSD, addiction and other conditions. Unusually, they are also one of the very few issues that have support across the political spectrum. This week, we discuss why this is a turning point for psychedelics and what might come next with Anne Philippi, a former journalist at Vogue, Vanity Fair, and GQ who now runs The New Health Club, a media organization dedicated to psychedelics. Learn more about your ad choices. Visit podcastchoices.com/adchoices